# Phase I Study of Ascending Doses of MMV390048 in Healthy Adult Volunteers

> **NCT02230579** · PHASE1 · COMPLETED · sponsor: **Medicines for Malaria Venture** · enrollment: 48 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** MMV390048 5mg
- **DRUG:** MMV390048 20mg
- **DRUG:** MMV390048 40mg
- **DRUG:** MMV390048 80mg
- **DRUG:** MMV390048 120mg
- **DRUG:** Placebo to match MMV390048

## Key facts

- **NCT ID:** NCT02230579
- **Lead sponsor:** Medicines for Malaria Venture
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2019-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02230579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02230579, "Phase I Study of Ascending Doses of MMV390048 in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02230579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*